HLB challenged for a second FDA approval for commercialization but failed. HLB logo. /Courtesy of HLB HLB's stock is trading at 46,500 won, down 19,900 won (29.97%) compared to the previous ...

The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...

Instead, they modify patented, FDA-approved medicines by adding an additional ... All republished articles must include our logo, our reporter’s byline and their DCNF affiliation.

"We are looking forward to building familiarity with the new REYOBIQ™ name and logo, as we believe it will ... versus currently approved therapies, with a more targeted and potent radiation ...

In India, GoRoga is already making an impact, being integrated into one of the country's top engineering institutes to help students manage stress and anxiety. Mrs. Mazumdar emphasized GoRoga's ...

“We are looking forward to building familiarity with the new REYOBIQ™ name and logo, as we believe it will foster stronger ... improve outcomes for CNS cancer patients, versus currently approved ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

Amgen (AMGN) announced that the U.S. FDA has approved Uplizna as the first and only treatment for adults living with Immunoglobulin G4-related ...

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...